Taysha Gene Therapies (TSHA) reported its financial results for the third quarter of 2025, with earnings per share (EPS) meeting expectations at a loss of $0.09. Despite the alignment with forecasts, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback